A Multi-functional Approach
Multi-functional immuno-recruitment proteins (MIRP) utilize cancer cell overexpression of checkpoint antigens compared to healthy cells to selectively target and bind to the cancer.
MIRPs deliver a multilayered attack by bridging/binding cancer cells and immune cells to produce a targeted synergistic effect. This effect is achieved by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
KAHR’s lead product, DSP107, is a clinical stage CD47x41BB targeting compound. DSP107 activates the innate immune system by blocking "Don’t Eat Me" signals on cancer cells while simultaneously recruiting and activating the adaptive immune system by providing co-stimulation signals to tumor localized T cells.
MIRPs deliver a multilayered attack by bridging/binding cancer cells and immune cells to produce a targeted synergistic effect. This effect is achieved by combining immune checkpoint inhibition with localized immune cell activation, unmasking cancer cell camouflage to enable innate immune response, while recruiting the adaptive immune system to bind and selectively kill the cancer cells.
KAHR’s lead product, DSP107, is a clinical stage CD47x41BB targeting compound. DSP107 activates the innate immune system by blocking "Don’t Eat Me" signals on cancer cells while simultaneously recruiting and activating the adaptive immune system by providing co-stimulation signals to tumor localized T cells.
Contact Us
KAHR 1 Kiryat Hadassah JBP Bldg. POB 9779, Jerusalem, 9109701, Israel T. +972.73.7969196 info@kahr-medical.com